ArticleCancer medicine2026
Pancreatic Metastasis of Clear Cell Renal Cell Carcinoma: Challenges in Percutaneous Biopsy and Contrast-Enhanced Ultrasound Imaging Features.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesThe objective of this study is to investigate the value of conventional ultrasound, contrast-enhanced ultrasound (CEUS) and percutaneous ultrasound-guided biopsy in the diagnosis of pancreatic metastases from clear cell renal cell carcinoma (ccRCC).
methodsA retrospective database search was conducted to identify all pancreatic lesions performed CEUS and final diagnosed as metastasis from ccRCC at our institution from September 2017 to June 2024. All enrolled patients were considered unsuitable for endoscopic ultrasound (EUS)-guided tissue acquisition, had failed EUS-guided biopsy, or required an alternative diagnostic approach. A total of 23 patients were enrolled in this study. Demographics, clinical features, ultrasound and CEUS findings, biopsy procedures, and results were collected and reviewed.
resultsOf the enrolled patients, metachronous metastasis was 100%. The median interval time from tumor-nephrectomy to the emergence of the pancreatic metastasis was 121.0 months (range: 46.0-276.0 months). Ultrasonography revealed rounded, well-defined, homogeneous hypoechogenic lesions in all the patients. Color Doppler flow image findings displayed plenty of blood flow signals around and inside the pancreatic lesions in 87.0% of patients. 22 patients (95.7%) exhibited rapid hyper-enhancement in the arterial phase of CEUS and 1 patient (4.3%) showed iso-enhancement. In the venous phase, 15 cases showed sustained hyper-enhancement and 8 cases showed iso-enhancement. In the biopsy procedure, ultrasound-guided core needle biopsy demonstrated higher diagnostic yield than fine needle aspiration (75.0% vs. 46.7%). The biopsy diagnosis was positive in 13 patients (65.0%) in general.
conclusionsMetastatic tumors of the pancreas can occur after a prolonged period from ccRCC diagnoses, thus long-term follow-up is necessary. The features of the lesion by conventional ultrasound and CEUS were specific, which are valuable for diagnosis. In patients who are unsuitable for EUS-guided tissue acquisition or have experienced unsuccessful EUS-guided sampling, CEUS combined with percutaneous ultrasound-guided biopsy may serve as a valuable complementary second-line diagnostic approach and facilitate accurate diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.